Quarterly report · Q2
3034.TEDINET S100PL5A
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥82.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥166.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥81.8bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥4.0bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥4.2bn | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥4.2bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥10.1bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.3bn | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥4.2bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥4.3bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.4bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥5.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.5bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.4bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥2.5bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥91.0bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥96.0bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥97.6bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥45.1bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥52.1bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥45.9bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥43.9bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥41.1bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥14.5bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥16.7bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥14.3bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥16.5bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥16.2bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥19.5bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥4.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥10.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.6bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥3.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.8bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥5.2bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥10.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥4.1bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥64.11 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥36.92 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥149.51 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥66.98 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥38.76 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 50.4% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 45.7% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 42.1% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥181m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥181m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥1.7bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥75.6bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥75.6bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥58m |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥5.1bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥7.0bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥6.9bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥123m |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥645m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥82.6bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥82.5bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥181m |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥5.7bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥193m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥193m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥1.7bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥75.4bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥75.3bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥40m |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥5.2bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥6.6bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥6.5bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥153m |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥663m |
| —segment total | revenue | 2021-04-01 → 2021-09-30 | ¥82.0bn |
| —segment total | revenue external | 2021-04-01 → 2021-09-30 | ¥81.8bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥193m |
| —segment total | segment profit | 2021-04-01 → 2021-09-30 | ¥5.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 524
| Item | Context | Value | Unit |
|---|---|---|---|
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of comprehensive income (text) | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated statement of cash flows (text) | CurrentYTDDuration | Text · Plus | |
| Notes additional information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Debtors notes regarding overdraft contracts and or loan commitments (text) | CurrentQuarterInstant | Text · Plus | |
| Major components of selling general and administrative expenses (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding gain on reversal of provision for withdraw loss from employees pension fund (text) | CurrentYTDDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |